Background: Insufficient vitamin D status has been linked to insulin resistance and cardiovascular disease. Serum 25-hydroxyvitamin D (25(OH) D) is also involved in immune activation and inflammation. High-sensitivity C-reactive protein (hs-CRP) is an inflammatory biomarker that has been associated with increased risk of cardiovascular disease and metabolic syndrome in observational studies. We aimed to investigate the association between serum 25(OH)D and hs-CRP in an observational study (the sixth Tromsø study), and to evaluate whether supplementation with cholecalciferol has any effect on hs-CRP in an interventional study (the Tromsø vitamin D and type 2 diabetes mellitus trial).
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Background
Vitamin D is a fat-soluble vitamin with a main function of maintaining bone mineral content through regulation of calcium and phosphorus homeostasis [1] . In the past few decades, nonclassical actions of vitamin D have been studied with increased attention, such as its impact on innate and adaptive immunity and involvement in immune-mediated disorders such as infections, autoimmune disease and cancer [2] [3] [4] [5] [6] . Recent observational studies reported significant associations between low serum 25-hydroxyvitamin D (25(OH) D) concentrations and increased risk of metabolic syndrome, hypertension, hyperglycemia and Cardiovascular Disease (CVD) [7] [8] [9] [10] . Inflammation has a well-established pathogenic role in these conditions, as well as in obesity and Type 2 Diabetes Mellitus (T2DM) , and obese subjects and/or subjects with T2DM demonstrate elevated levels of inflammatory biomarkers such as fibrinogen, white blood cells and C-Reactive Protein (CRP) [11, 12] .
CRP is an inflammatory marker that is synthesized and secreted predominantly by hepatocytes in response to proinflammatory cytokines, such as Tumor Necrosis Factor Α (TNF-α), Interleukin-1 (IL-1) and Interleukin-6 (IL-6) [13, 14] . In a number of observational studies, CRP was a strong predictor of metabolic syndrome and cardiovascular disease and the results from the Rotterdam study (a large population-based cohort study) showed that serum CRP was associated with elevated risk of T2DM independent of overweight and obesity [15] [16] [17] [18] [19] High-sensitivity CRP (hs-CRP) measures CRP at very low concentrations, between 3 and 10 mg/L. Hs-CRP is considered to be a biomarker of low-grade inflammation , which is strongly associated with atherosclerosis, obesity and prediabetes [20, 21] .
The relationship between serum 25 (OH) D concentrations and CRP (or hs-CRP) has been investigated in several studies, with inconsistent results [22] [23] [24] . We have therefore aimed to investigate the association between serum 25(OH)D concentration and hs-CRP based on both an observational study (the sixth Tromsø Study) and a 5-year interventional study (Tromsø vitamin D and T2DM trial: vitamin D vs. placebo in subjects with prediabetes).
Materials and methods

Observational study: the sixth Tromsø Study
The Tromsø Study, conducted by the University of Tromsø in cooperation with the National Health Screening Service of Norway, is a longitudinal, population-based, multipurpose study focused on lifestyle-related diseases [25, 26] . The sixth survey of the Tromsø Study was performed in 2008, in which 19,762 subjects were invited and 12,984 responded. The participants completed questionnaires about lifestyle factors, including consumption of cod liver oil, use of vitamin D supplements, and smoking. Only non-smoking subjects (n=10,118) were included. Non-fasting blood samples were drawn for later measurements of hs-CRP, glycated hemoglobin (HbA1c) and serum. 
Interventional study (5-year intervention): Tromsø vitamin D and T2DM trial
The recruitment of subjects and the procedure of randomization is described in detail elsewhere [27] .Briefly, the inclusion criteria were age of 21-80 years and a diagnosis of prediabetes. Prediabetes was defined as an impaired fasting glucose (IFG) level of >6 mmol/L or <7.7 mmol/L) and/or Impaired Glucose Tolerance (IGT) with a 2-h glucose of >7.7 mmol/L or <11.1 mmol/L on an Oral Glucose-Tolerance Test The exclusion criteria were a history of coronary infarction, angina pectoris, stroke, sarcoidosis, cancer in the preceding 5 years, renal stones, nut allergies or reduced kidney function (creatinine of >125 µmol/L in men and 105 µmol/L in women). Subjects were also excluded if they used weight-reducing drugs or antidepressant medications, were pregnant or lactating, or were females younger than 50 years and not using adequate contraception.
Each participant's medical history was recorded, including smoking habits and use of calcium and vitamin D supplementation. Height and weight were measured with the subjects wearing light clothing and no shoes. BMI was calculated as weight (kg) divided by height squared (m 2 ). The study medication was cholecalciferol capsules (vitamin D3 20,000 IU [Dekristol; Mibe, Jena, Germany]) or a placebo in the form of identical-looking capsules containing arachis oil (Hasco-Lek, Wroclaw, Poland). The medication or the placebo was taken as one capsule per week. The subjects were not allowed to take vitamin D supplements (including cod liver oil) exceeding 400 IU/day. At the baseline visit, nonfasting blood samples were drawn. Body measurements and laboratory evaluations were repeated annually during the 5-year intervention.
Laboratory measurements
Height, weight, HbA1c, plasma glucose, serum parathyroid hormone, insulin and hs-CRP were measured. Serum levels of 25(OH) D in the observational study were measured by immunometry (electro chemiluminiscent immunometric assay) using an automated clinical chemistry analyser (Modular E170; Roche Diagnostics GmbH, Mannheim, Germany). The total analytical Coefficient of Variation (CV) for the vitamin D assay was 7.3% based on consecutive donor control measurements (65.0 nmol/L) during the analytical period, using a qualitymanagement program (QM; Tieto Enator, Helsinki, Finland). The cross-reactivity with 25(OH) D2 was less than 10%, and the analytical sensitivity was 10 nmol/L. At present, the laboratory has no reference values for 25(OH) D, but the manufacturer provides a population-based reference range of 27.7-107.0 nmol/L for adults as a guideline. This analysis was approved by the Norwegian Accreditation Authority. Because this method seems to overestimate serum 25(OH) D in smokers, we chose to exclude current smokers from the analysis [28] .
In the interventional study, serum vitamin D was measured with in-house Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). The limit of detection was <4 mmol/L, and the between-day CV was <9% [29] . Hs-CRP concentrations were measured using the turbid metric method. The reagents and the measuring device were provided by Roche Diagnostics. The total analytic CV was 4.26%. 
Statistical analyses
All statistical analyses were performed using IBM SPSS version 21 software. The distribution of continuous variables was evaluated by visual inspection of histograms and by kurtosis and skewness. Correlations were analysed using Pearson's correlation coefficient, and between-group comparisons were performed using ANOVA. The associations between serum 25(OH) D and hs-CRP were analysed using the linear regression model, which was also used to test the interactions between variables.
In the interventional study, delta levels of hs-CRP were recorded for each year of intervention. The differences between delta values of hs-CRP in the vitamin D intervention group and the placebo group were evaluated with ANOVA. Furthermore, delta hs-CRP values for each year of the intervention were recorded in the dichotomous variables as follows: if the delta value was negative (indicating decreased hs-CRP), the dichotomous variable was coded as 1. If the delta value of hs-CRP was zero or was positive (indicating no effect or increased hs-CRP), the dichotomous variable was coded as 2. The logistic regression model was applied if intervention with vitamin D was a predictor of decreased hs-CRP during each year of the intervention after adjusting for age, sex, BMI, HbA1c and smoking status at baseline.
The data are presented as mean ± SD, unless otherwise specified. The significance level was set at P<0.05 (two-tailed).
Ethics
The study was approved by the Norwegian Medicines Agency and by the Regional Committee for Medical Research Ethics. The trial is registered at ClinicalTrials.gov (NCT00685594).
Results
In the observational study, a total of 10,118 non-smoking subjects had available measurements of serum 25(OH) D and hs-CRP. The demographics of the study population are provided in (Table 1 ). There were no significant differences in serum 25(OH) D and hs-CRP levels between the men and women. Men had significantly higher BMI, waist circumference and HbA1c. In the total study population, there was a significant negative correlation between serum 25(OH) D and hs-CRP, resulting in a Pearson correlation coefficient r of −0.05 (P=0.001). In the linear regression model, after adjusting for age, sex, BMI, HbA1c and waist circumference, a 1 nmol/L increment in serum 25(OH)D resulted in a 0.02 mg/L decrease in hs-CRP (P=0.03). As there were significant interactions between BMI, serum 25(OH) D and sex, we performed a sex-stratified analysis. When analysing the genders separately, the negative association was statistically significant only in the women, resulting in a Pearson correlation coefficient r of −0.06 (P=0.001) and a β coefficient of −0.03 (P=0.03) ( Table 2) . With regard to the interventional study, the flowchart for this Randomized-Controlled Trial (RCT) is provided in (Figure 1 ). Five hundred fifty-six subjects were included, and 278 were randomly assigned to the placebo group. Twenty-two subjects who were allocated to the vitamin D intervention group and 23 who were allocated to the placebo group were excluded at the baseline visit (two did not meet the inclusion criteria, and 43 met one or more exclusion criteria). A total of 511 participants were finally included, 256 in the vitamin D group and 255 in the placebo group. At baseline, there were no significant correlations 
Effects of intervention
At baseline, there were no differences between the vitamin D group and the placebo group with regard to age (68±8 years and 68±9 years, respectively) and sex (63% males and 60% females, respectively). There was also no difference in vitamin D supplement use (n=87 [34.0%] in the vitamin D group versus n=92 [36.1%] in the placebo group). The baseline values and the values after each year of intervention are presented in (Table 3) . There were no significant differences between the vitamin D and placebo groups in delta values of hs-CRP during any part of the 5-year intervention (Table 4 ).
In the logistic regression model, vitamin D intervention was associated with an increased odds ratio for delta hs-CRP of >0 for each year of intervention; however, the statistical significance of
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Discussion
In our observational study, we demonstrated that in the nonsmoking population, a 1 nmol/L increment of serum 25(OH) D led to a 0.02 mg/L decrease in hs-CRP. This association remained statistically significant only in women after the sexstratified analysis. To investigate the causality of this association, we determined whether supplementation with 20,000 IU of cholecalciferol each week decreased hs-CRP levels during a 5-year intervention. At baseline, there was a negative but not significant association between serum 25 (OH) D concentrations and hs-CRP in 556 subjects who were prediabetic but otherwise healthy. We found no hs-CRP-lowering effect from cholecalciferol supplementation; these findings were consistent for each year of the intervention and were independent of age, sex, BMI, HbA1c and smoking status. Thus, to our knowledge, our study is the first to investigate the exposure-outcome relationship between serum 25(OH) D and the inflammatory biomarker hs-CRP from both observational and causal perspectives.
Recent studies have suggested the role of 25(OH) D in lowintensity chronic inflammation in healthy and T2DM subjects [30, 31] . To our knowledge, there have been few RCTs in which inflammatory biomarkers, including hs-CRP, were secondary outcomes [30] . Our interventional study (the Tromsø vitamin D and T2DM trial) is the only RCT to date with a follow-up period as long as 5 years. Our finding of a negative association between serum 25(OH) D and hs-CRP in the observational study is consistent with previous reports. An inverse association between serum 25 (OH) D concentrations and hs-CRP was found in subjects with cardiovascular disease, middle-aged and older adults and subjects with overweight and obesity [32] [33] [34] [35] . Furthermore, Tepper et al. studied 358 healthy males and found that serum 25(OH)D levels were negatively associated with hs-CRP at a threshold of 14 ng/ml. Mellenthin et al. in a large observational study based on 2,723 subjects, reported that the inverse correlation between serum 25(OH) D and hs-CRP was only present in subjects with serum 25(OH) D levels of <21 ng/ml. Interestingly, when they further stratified the population according to smoking status, the association was no longer significant in non-smokers (n=2,005) [36, 37] . This particular observation is contrary to our study. However, we included a subgroup of non-smokers that was more than 5-fold larger (n=10,118); the lack of this association in non-smokers in Melenthin et al. Study can be explained by an insufficient number of subjects [37] . This association has a biologically plausible explanation: vitamin D binds to high-affinity Vitamin D Receptor (VDR) in mast cells, CD4 and CD8 lymphocytes, and macrophages, which may interfere with systemic inflammation and inhibit the production of several proinflammatory cytokines that modulate the tissue immune response and restrict inflammation [38, 39] . Nuclear Factor Kappa B (NFκB) pathway-dependent transcriptional activation is a well-known signaling pathway in inflammation and a major regulator of the immune response. NFκB activation is also involved in endogenous CRP induction. The biologically active form of vitamin D, 1, 25-dihydroxyvitamin D3 (1, 25(OH) 2D3), can inhibit NF-kB activation in macrophages by up regulating the NFκB inhibitor [40] . This suggests that promoting higher concentrations of serum 1, 25(OH) 2D may suppress CRP by interfering with the NFκB pathway. A similar action with cholecalciferol supplementation was expected, but we were unable to confirm these effects in our 5-year intervention.
Prior RCTs assessing whether vitamin D supplementation lowered hs-CRP levels reported inconsistent results [27, [41] [42] [43] . A noteworthy meta-analysis of 10 Moreover, the vitamin D-deficient subjects (serum 25(OH) D <20 ng/ml) had significantly higher expression of the proinflammatory cytokines NFκB and IL-6; however, no effect on TNF-α was seen.
In our prior RCT, overweight and obese subjects were randomised into three groups: the DD group (40,000 IU cholecalciferol per week), the DP group (20,000 IU cholecalciferol per week) and the PP group (placebo) [41] . The intervention period was one year, and the proinflammatory cytokines IL-6, TNF-α and hs-CRP were secondary outcomes. Consistent with the study by Jablonski et al. we found an effect of vitamin D supplementation on IL-6 lowering when the DD and DP groups were analysed together, but there were no significant changes in TNF-α [33] . Interestingly, we found an increment in hs-CRP after one year of cholecalciferol supplementation in overweight/ obese subjects. In the present study, we observed that after the second year of intervention, supplementation with 20,000 IU of cholecalciferol was associated with an almost 50% increase in the odds ratio of zero/positive delta hs-CRP values, and the participants had prediabetes. Since the same observation was not made after other intervention years, this finding was most likely due to chance or other factors (including ongoing proinflammatory conditions such as obesity or prediabetes) and should be treated with caution, at least in subjects with conditions such as prediabetes, overweight and obesity.
Our study has some potential limitations. The first and major limitation regards the interventional part of our study. The statistical power calculation was based on the hypothesis that T2DM would be prevented by cholecalciferol supplementation, and the primary outcome was the occurrence of T2DM. Second, when using inflammatory biomarkers as an outcome in both the observational and the interventional studies, it would be helpful to have data on whether the subjects were using Non Steroidal Anti-Inflammatory Drugs (e.g. NSAIDS) or had any inflammatory conditions (e.g. infection, latent autoimmune disease). This information was absent in our study. Finally, our intervention was performed on subjects with prediabetes, which is per se a
